Dorea

Dorea is a normal resident of a healthy colon, and finding it in your stool is expected. What makes it worth looking at is that its numbers move in a fairly consistent direction across human studies: higher in people with fatty liver, higher body mass index, and prediabetes; lower in people with active gut inflammation, recent antibiotics, and some autoimmune conditions.

This is a research-grade measurement, not a diagnostic one. There are no validated cutoffs, no threshold that means anything on its own, and no evidence that screening healthy people for it catches disease earlier. Read it as one line in a broader microbiome picture, and read it over time rather than once.

What This Bacterium Actually Does

Dorea belongs to the Lachnospiraceae family, a large group of oxygen-avoiding bacteria that make up a core part of the healthy colon. Its main job is fermentation. It takes the fiber and complex carbohydrates your own digestive enzymes cannot break down and converts them into small molecules and gases. Culture studies of the main human species put acetate, formate, lactate, ethanol, hydrogen, and carbon dioxide among the products, and show these bacteria do not make butyrate or propionate, the two short-chain fatty acids most often credited with gut and metabolic benefits.

One other function matters for interpreting your result. Genomic analysis shows the genus carries the gene cluster that converts bile acids into secondary bile acids, and a 2025 study confirmed that Dorea ammoniilytica produces deoxycholic acid, one of the main secondary bile acids in the human gut. Those molecules affect how your gut barrier holds up, how you absorb fat, and how much low-grade inflammation circulates in your body. Fiber fermentation and bile acid handling both run through this one genus, which is part of why it keeps appearing in metabolic studies.

The test detects bacterial DNA in your stool. Most panels use PCR to copy a stretch of the 16S rRNA gene, which differs just enough between bacterial groups to tell them apart. What comes back is a relative abundance: how much of the total bacterial DNA in your sample belongs to this genus, not an absolute count of live cells.

Fatty Liver and Metabolic Disease

The strongest and most repeated finding is that Dorea runs high in people with fat accumulating in the liver. In a study of 106 adults, stool Dorea was clearly enriched in people with metabolic associated fatty liver disease and rose with the degree of liver enzyme abnormality. A separate study in children with biopsy-confirmed liver disease found the same pattern: a rise in Dorea was one of the microbial signatures distinguishing nonalcoholic fatty liver disease from healthy controls and from obesity alone.

The direction is not uniform once you look below the genus. In a randomized probiotic trial in nonalcoholic fatty liver disease, several Dorea sequence variants moved with improvement in liver fat and body mass index, while a different one moved with weight gain. So the headline association is a genus-level generalization that individual species and strains contradict, and a 16S panel cannot tell you which ones you are carrying.

The obesity link holds up at scale. A pooled analysis of 7,415 European adults across eight observational studies found that a higher body mass index came with lower overall gut diversity and higher odds of detecting Dorea. At the species level, a cross-sectional study of overweight, obese, and lean adults found Dorea longicatena and Dorea formicigenerans were both elevated in the heavier groups, with longicatena tracking waist circumference and formicigenerans tracking body weight.

Blood sugar follows the same direction. A case-control study of 268 adults found that people with prediabetes had more Dorea alongside less Clostridium, and its abundance ran with HbA1c, insulin, insulin resistance, an inflammation marker, body mass index, and waist circumference. Similar enrichment appears in people with established type 2 diabetes. What links the bacterium to the metabolic state is not worked out. Bile acid handling and gut barrier effects are the usual proposals, and neither has been shown to cause anything in humans.

A high result does not diagnose fatty liver or insulin resistance. It is a prompt to check the markers that do. If your number sits at the high end, the useful next move is a liver enzyme panel, fasting insulin, and HbA1c, not a supplement aimed at the bacterium.

Why Low Can Also Mean Trouble

A simple high-is-bad reading falls apart here. Depleted Dorea shows up in a different set of conditions entirely. In quiescent Crohn's disease, it is markedly reduced alongside lower short-chain fatty acids. In kidney transplant recipients with non-infectious diarrhea, it drops and then recovers after fecal microbiota transplantation. It is reduced in primary Sjögren's syndrome, where lower levels track with worse disease severity, and in severe bipolar depression and diabetic retinopathy.

Both patterns can be true because this is not a good-number-bad-number marker. It is an ecological indicator, and two different things can push it in opposite directions. A high-fermentable-carbohydrate, high-adiposity state favors its expansion. Acute inflammation, rapid colonic transit, mucosal damage, and antibiotics wipe out fiber-fermenting anaerobes as a class, and Dorea goes down with them. A low result usually means the fermenting community as a whole has been disrupted, not that this one genus is specially important.

So your result only means something in the context of the rest of your panel. Low Dorea with low Faecalibacterium, low Roseburia, and low butyrate is a picture of broad loss of fiber fermenters. Low Dorea by itself, with everything else intact, is close to noise.

Kidney Disease and Colorectal Polyps

In end-stage renal disease, higher Dorea abundance tracks with altered secondary bile acid pathways. A metagenomic study of 715 people found gut microbial changes in end-stage renal disease that predicted the uremic toxins circulating in blood, with Dorea among the taxa involved. Elevated levels have also been reported in people found to have precancerous colon polyps, though that finding is inconsistent: at least one recent cohort found no taxa that reliably separated people with adenomas from those without.

Both of these are associations in disease cohorts, not screening evidence. Nobody has shown that measuring Dorea finds kidney disease or polyps earlier than the tests already used for that. A colonoscopy remains the way to find polyps. A cystatin C or creatinine-based kidney panel remains the way to assess kidney function.

Outcome Evidence Is Thin

There are no large prospective cohorts linking stool Dorea to death, heart attack, or cancer incidence. The hard-endpoint studies that do exist are small and specific. In a cohort of 210 hospitalized people with antibiotic-associated diarrhea plus 100 healthy controls, where one in five of the hospitalized patients died during the stay, Dorea was one of five genera whose abundance ran opposite to mortality: more of it, fewer deaths. The formal risk estimates in that study were calculated for antibiotic resistance genes, not for this genus.

Two pediatric studies point the same way. In 55 infants with biliary atresia followed after Kasai surgery, those who went on to need a liver transplant had significantly less Dorea at 24 weeks than those who kept their native livers. In 51 children with hypertension matched against 51 controls, Dorea held an independent inverse relationship with high blood pressure even after adjusting for body mass index and environmental factors, and adding it to a model with body mass index improved how well the model separated the two groups.

Notice that these hard-outcome studies all point the other direction from the metabolic ones: more Dorea, better outcome. That is consistent with the ecological reading. In acutely ill and post-surgical populations, its presence marks an intact fermenting community. In metabolically stressed but otherwise healthy adults, its overgrowth marks a different problem. The population you belong to determines which reading applies.

What Actually Moves It

Antibiotics lower it, and the longer the course the lower it goes. Corticosteroids came with lower levels in the same hospitalized cohort. Systematic reviews of antibiotic effects on the gut show disruption that can last from weeks to years, though those reviews do not break results out by genus.

One probiotic lowered it in a randomized trial. Twelve weeks of Lacticaseibacillus paracasei DG in people with non-constipated irritable bowel syndrome significantly reduced fecal Dorea, but only in the people who responded clinically to the probiotic. Responders had started with more of it than non-responders.

Fiber did not raise it in the one study that looked. Four weeks of a high-fiber diet plus lactulose in people with Parkinson's disease improved short-chain fatty acids and symptoms, but did not restore depleted Dorea. Whatever had suppressed it was not a short-term fiber deficit.

Why a Single Reading Can Fool You

Variability is the single most important thing about interpreting this number. In healthy adults sampled daily for six weeks, more than three quarters of gut genera varied more within one person over time than they did between different people, and swings inside a single person reached a hundredfold. How loose or firm the sample was explained a meaningful chunk of that variation, and diet explained some more.

Over longer windows the picture steadies. A one-year study of 75 healthy adults found that within-person variation accounted for 23% of total compositional variance, and the authors recommended repeated sampling rather than trusting any single draw. Over two years, genus-level stability was generally good. So the community has a stable center of gravity that a single snapshot can easily miss.

• Recent antibiotics or steroids: these suppress fiber-fermenting anaerobes broadly. A sample taken during or soon after a course tells you about the drug, not your baseline.
• Stool consistency on the day: looser stool shifts measured abundance independently of any change in your actual gut community.
• Lab method: sequencing platforms, the region of the 16S gene each lab targets, the DNA extraction method, and the software pipelines all change the number that comes back from the same sample. Results from two providers are not directly comparable.
• Recent acute illness or diarrhea: rapid transit strips out slow-growing anaerobes temporarily.

Tracking Your Trend

One reading of this marker is close to uninterpretable. Given how much stool genera fluctuate day to day, the number you get reflects that week as much as it reflects you. The trend is the signal.

Get a baseline. If you are making a real change, a sustained shift in fiber intake, a course of probiotics, recovery from antibiotics, retest at 3 to 6 months. After that, annually is a reasonable cadence for anyone actively tracking metabolic health. Use the same lab every time, because cross-provider numbers do not line up.

Retesting can confirm less than you might hope. The probiotic evidence here is specific: one strain, twelve weeks, in irritable bowel syndrome responders. The fiber evidence showed no change over four weeks. If you retest hoping to see a supplement working, there is very little direct evidence that most interventions move this particular genus in a predictable way.

What to Do With an Out-of-Pattern Result

Start by reading it alongside the rest of the panel rather than in isolation. A high result paired with low overall diversity, low butyrate, and a low Faecalibacterium is a different situation from a high result in an otherwise rich and balanced community.

If your level runs high and you have any metabolic risk factors, the informative next step is blood work, not another stool test. Check ALT and AST, the liver enzymes that rise when liver cells are stressed. Add fasting insulin, HbA1c, and a lipid panel. That combination tells you whether the metabolic pattern the Dorea literature describes is actually present in your body. If those come back abnormal, imaging for liver fat and a conversation with a hepatologist or endocrinologist become worthwhile.

If your level runs low and you have ongoing gut symptoms, the question is whether there is inflammation driving it. Fecal calprotectin is the direct test for inflammation in the gut lining, and a persistently elevated calprotectin with diarrhea or blood is a gastroenterology referral, not a supplement problem. If your level is low and you feel fine, the most likely explanation is a recent antibiotic course or a loose sample. Wait a few months and retest before doing anything.

One thing not to do: treat a Dorea result as evidence of infection. This is a normal gut resident. No amount of it warrants antimicrobial treatment, and PCR detection of bacterial DNA says nothing about whether those cells were alive or causing harm.